Paolo Fundaró

Paolo has been Genextra’s Chief Financial Officer since its inception in 2004 and from 2019 he is the Chief Executive Officer. Paolo has served as a member of the board of directors of various Genextra’s portfolio companies. In particular, he is currently Chairman of Intercept Pharmaceutical, member of the board of directors of Erydel and TargImmune Therapeutics. In addition, Paolo is also a founder and a Board Member of the Italian Angels for Biotech and a board member of Tiscali. Before joining Genextra, Paolo was in charge of finance and strategic planning for FastWeb from 2000 to 2004. Previously, he worked in London for investment banks, including Salomon Smith Barney (now Citigroup) and Donaldson Lufkin & Jenrette (now Credit Suisse). Paolo has a degree cum laude in Business Management from Bocconi University in Milan, Italy.